Vaxart (OTCMKTS:VXRT) Issues Quarterly Earnings Results

Vaxart (OTCMKTS:VXRT) issued its earnings results on Thursday. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.32, reports. The firm had revenue of $104.24 million for the quarter, compared to analysts’ expectations of $35.95 million. Vaxart had a negative return on equity of 123.53% and a negative net margin of 34.21%.

Here are the key takeaways from Vaxart’s conference call:

• Dynavax collaboration provides a $25M upfront payment plus a $5M equity investment, extends cash runway, and gives Vaxart eligibility for up to an additional $50M near-term and a total potential economic value of up to $700M including milestones and royalties.
• The Dynavax acquisition by Sanofi closed Feb 10, 2026 and Vaxart reports a productive working relationship with the combined team, which could enhance development and commercialization prospects for the oral COVID-19 candidate.
• The Phase 2B COVID-19 trial timing is managed with BARDA oversight — top-line 12‑month safety data from the 400‑person sentinel cohort is expected in early Q2 2026 (slightly delayed from prior guidance) while efficacy readouts from the ~5,000‑person KP2 cohort are expected in late Q4 2026.
• Published Phase 1 data for the oral norovirus vaccine in lactating mothers showed the vaccine was well tolerated and produced statistically significant rises in serum and breast‑milk IgA with exploratory evidence of passive transfer to infants, and second‑generation constructs showed substantially higher antibody responses in head‑to‑head testing.
• Financials show 2025 revenue rose to $237.3M (driven by BARDA and Dynavax recognition) but cash and investments stood at $63.8M with an expected runway into Q2 2027, prompting ongoing pursuit of partnerships, non‑dilutive funding, and cost reductions (e.g., lease termination) to avoid near‑term financing pressure.

Vaxart Stock Down 8.0%

Vaxart stock traded down $0.06 during mid-day trading on Friday, hitting $0.68. 746,522 shares of the company’s stock were exchanged, compared to its average volume of 881,899. The company’s 50 day simple moving average is $0.63 and its 200-day simple moving average is $0.46. The firm has a market capitalization of $163.24 million, a P/E ratio of -2.95 and a beta of 1.17. Vaxart has a fifty-two week low of $0.26 and a fifty-two week high of $0.84.

Institutional Investors Weigh In On Vaxart

Several large investors have recently modified their holdings of the business. Marshall Wace LLP acquired a new stake in Vaxart in the 2nd quarter valued at approximately $794,000. Jones Financial Companies Lllp boosted its position in Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 478,111 shares during the last quarter. Raymond James Financial Inc. grew its stake in shares of Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after acquiring an additional 34,075 shares in the last quarter. Invesco Ltd. grew its stake in shares of Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 70,568 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Vaxart in the first quarter valued at approximately $31,000. 18.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Vaxart to a “buy” rating in a research report on Friday, January 23rd. One analyst has rated the stock with a Buy rating, According to MarketBeat, Vaxart has a consensus rating of “Buy” and an average price target of $2.00.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.